Skip to main content

Table 2 Characteristics of the juvenile idiopathic arthritis group (n = 42)

From: Serum and salivary inflammatory biomarkers in juvenile idiopathic arthritis—an explorative cross-sectional study

Clinical characteristics

Value

Age at study visit, years, median (IQR)

13.9 (11.3–15.1)

Age at disease onset, years, median (IQR)

8.4 (2.7–11.1)

Disease duration, years, median (IQR)

4.8 (2.8–8.3)

JIA categorya, n (%)

 Oligoarticular persistent

15 (35.7)

 Oligoarticular extended

3 (7.1)

 Polyarticular RF negative

10 (23.8)

 Psoriatic

2 (4.8)

 Enthesitis-related

8 (19.0)

 Undifferentiated

4 (9.5)

ANA positiveb, n (%)

14 (35.0)

HLA-B27 positive, n (%)

13 (31.0)

Disease activityc, n (%)

 Remission off medication

12 (28.6)

 Inactive

9 (21.4)

 Active

21 (50.0)

JADAS71d > 0, n (%)

28 (70.0)

PhysGA VAS > 0, n (%)

14 (33.3)

Number of individuals with active jointse, n (%)

9 (21.4)

DMARDsf ongoing, n (%)

24 (57.1)

Steroids ongoing, n (%)

2 (4.7)

NSAIDs ongoing, n (%)

15 (35.7)

No medication, n (%)

13 (31.0)

  1. JIA juvenile idiopathic arthritis, IQR inter-quartile range, ANA antinuclear antibodies, RF Rheumatoid factor, HLA-B27 human leukocyte antigen B27, JADAS71 Juvenile Idiopathic Arthritis Activity Score based on 71 joints, VAS visual analog scale, PhysGA VAS physician’s global assessment of disease activity using a 21 numbered circle VAS (0 = no activity, 10 = maximum activity), DMARDs disease-modifying anti-rheumatic drugs, bDMARDs biologic DMARDs, NSAIDs non-steroid anti-inflammatory drugs
  2. aAccording to the International League of Association for Rheumatology (ILAR) classification criteria. Only non-systemic JIA categories were included. No children had RF positive polyarticular JIA
  3. b ANA positive is defined as two positive ANA tests with HEp-2 substrate measured at least 3 months apart
  4. c Disease status according to Wallace et al. Remission off medication = inactive disease off medication for ≥ 12 months. Inactive = inactive disease on medication for < 6 months, or off medication < 12 months, or remission on medication (inactive disease on medication for ≥ 6 months). Active = continuous active disease or flare
  5. d JADAS71 is a composite scoring tool measuring disease activity (range 0–101 0 = no activity, 101 = maximum activity), consisting of the physician’s global assessment of disease activity VAS (0–10), the parents/patient global assessment of disease impact on wellbeing VAS (0–110), the number of active joints (0–71), and the normalized erythrocyte sedimentation rate (ESR) (0–10). (2 missing)
  6. e Number of participants with physician-determined swollen joints or joints with loss of range of motion and joint pain or tenderness
  7. f Either synthetic (methotrexate and mycophenolate mofetil) and/or biologic (etanercept, infliximab, adalimumab, certolizumab, tocilizumab, abatacept) DMARDs
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096